Psychedelics Investing Global Neuro-Psychiatric Disorders & Treatment Market Projected to Reach $166 Billion by 2032 01 July
Psychedelics Investing Compass Pathways Successfully Achieves Primary Endpoint in First Phase 3 Trial Evaluating COMP360 Psilocybin for Treatment-Resistant Depression 23 June
psychedelics investing Compass Pathways to Participate in 2025 RBC Capital Markets Global Healthcare Conference 14 May
